Floatz logo

Autologous Melanoma Lysate/Klh-Pulsed Autologous Dendritic Cell Vaccine

Rhabdomyosarcoma- Alveolar

National Cancer Institute (NCI)vaccinePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Rhabdomyosarcoma- Alveolar cohort.

Asset / SponsorPhaseRating
Rhil-7
National Cancer Institute (NCI)
Phase 1/2CCC
Allogeneic Tumour Lysate
National Cancer Institute (NCI)
Phase 1/2CCC
Klh-Pulsed Autologous Dendritic Cell Vaccine
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

Autologous Melanoma Lysate/Klh-Pulsed Autologous Dendritic Cell Vaccine is also rated in:

Rhabdomyosarcoma-EmbryonalDormant
CCC
Indicative ·
52 / 100
View asset →
Neuroectodermal Tumors, Primitive, PeripheralDormant
CCC
Indicative ·
52 / 100
View asset →
NeuroblastomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →